Item 1A. Risk Factors
 at "
Our term loan contains certain covenants that could limit our ability to plan for or respond to changes in our business." 
and
 Item 8
.
 Financial Statements—Audited Consolidated Financial Statements - 
Note 
12. Debt 
for additional information. In addition, substantially all of the assets of the Company are pledged to secure this debt. The restrictions under the Note Purchase Agreement substantially limit our ability to obtain other financing, other than the $50 million revolving credit facility.
Capital Resources
The Company believes its existing cash and cash equivalents and investments together with cash generated from operations and debt will enable its anticipated cash needs to be met, including working capital, capital expenditures, litigation settlement payments, milestone payments, income taxes, repurchase of ordinary shares, debt repayments and other funding requirements, for at least the twelve-month period 
115
following the issuance of this Form 10-K. T
he Company will have to sustain sales volume performance with no material change in the timing of its collections and rebate payments to maintain necessary liquidity in the near term and to meet our obligations in the long term. 
The Company is also subject to contingent liabilities as described in 
Item 8
.
 Financial Statements—Audited Consolidated Financial Statements—Note 16. Commitments and Contingencies
.
Capital Expenditures
For the years ended
December 31,
(in millions)
2024
2023
2022
Purchases of property, plant and equipment
$
(29)
$
(8)
$
(5)
Purchases of in-process research and development and intangible assets
(2)
(45)
(1)
Total

$
(31)
$
(53)
$
(6)
The Company’s capital expenditures for 2024 reflected the expansion of the Raleigh Manufacturing plant. Capital expenditures in 2023 and 2022 were primarily for equipment used in the manufacture of our products. The Company funded these expenditures from its existing cash balances.
IPR&D and intangible asset purchases for the years ended 2024, 2023 and 2022 were $2 million, $45 million, and $1 million, respectively, and were funded from existing cash balances. The 2023 cash paid includes $21 million for the acquisition of INDV-2000 (oral Orexin-1 receptor antagonist) from C4X Discovery and $15 million to secure the global rights to develop, manufacture, and commercialize Alar Pharmaceuticals Inc.’s portfolio of buprenorphine-based ultra LAI, including INDV-6001, the lead asset which is potentially the first three-month LAI for OUD.
Contractual Obligations
The table below sets forth the Company’s anticipated contractual cash flows including bank debt, legal settlement payments (including expected interest payments), share repurchase liabilities and lease liabilities on an undiscounted basis as of December 31, 2024.
December 31, 2024
(in millions)
Total
1 year or less
2-5 years
More than 
5 years
Debt
$
524 
$
53 
$
215 
$
256 
Litigation settlement liabilities
398 
85 
313 
— 
Commercial commitments
210 
88 
111 
11 
Capital expenditures
21 
21 
— 
— 
Lease liabilities
50 
13 
31 
6 
Share repurchase liabilities
5 
5 
— 
— 
Employee-related liabilities
12 
— 
— 
12 
Total

$
1,220

$
265

$
670

$
285

Potential milestone and royalty payments
The Company is party to collaboration and license arrangements for the development of pharmaceutical and digital products. Milestone payments will be due if various developmental, regulatory and commercial goals are achieved and in certain cases royalties will be payable as a percentage of net revenue, although the Company generally has the right to terminate these agreements at no cost. The Company has no significant milestone payments expected in 2025.
116
Agreements for contract manufacturing and supply of materials 
The Company is obligated to purchase specified amounts of goods or services under various contract manufacturing and material supply agreements over periods ranging from 1 to 6 years. These agreements could require us to pay approximately $210 million (before annual price index adjustments).
CVR Agreement
In connection with the acquisition of Opiant, a subsidiary of Indivior issued Contingent Value Rights (“CVRs”) to the shareholders of Opiant. Each CVR represents the obligation of Indivior Inc. to make cash payments upon achievement of certain worldwide net sales milestones during the period from October 1, 2023 to September 30, 2030.
Total potential payments could be up to a maximum of $68 million over a period of up to 7 years from the date of the first commercial sales of a new Opiant product. Refer to 
Item 8
.
 Financial Statements—Audited Consolidated Financial Statements—Note 18. Asset Acquisitions 
for additional details on the CVR agreement.
Research and Development Expenses, Patents and Licenses, etc.
See “